Clinically Advancing BDK Inhibitors

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Metabolic Disorders

Background:

• Physiopathology of cardiac and related disorders is linked to branched-chain amino acid (BCAA) metabolic imbalance.
• BCKD kinase (BDK) acts as a negative regulator of the BCAA catabolizing BCKDH complex.
• Dysregulation of BCAA catabolism is implicated in cardiovascular disease (CVD) pathogenesis.

Purpose of the Study:

• To investigate the role of BDK in BCAA metabolic dysfunction relevant to cardiac disorders.
• To evaluate PF-07328948, a potential BDK inhibitor, for its therapeutic potential in metabolic CVD.

Main Methods:

• The study focuses on the regulatory role of BDK in BCAA metabolism.
• Preclinical assessment of PF-07328948's drug-like properties.
• Phase-1 clinical trials are underway to assess PF-07328948 in metabolic CVD.

Main Results:

• BCAA metabolic imbalance is a key factor in cardiac disorder pathophysiology.
• BDK is identified as a significant regulator in BCAA catabolic dysfunction.
• PF-07328948 demonstrates promising drug-like properties for potential therapeutic use.

Conclusions:

• Targeting BDK may offer a novel therapeutic strategy for metabolic cardiovascular disorders.
• PF-07328948 represents a clinically relevant BDK inhibitor for CVD treatment.
• Further clinical investigation is warranted for PF-07328948 in managing metabolic CVD.